Cognitive behavioural therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective. Re-analysis of a Cochrane review.
Vink, Mark, Vink-Niese, Alexandra · Health psychology open · 2019 · DOI
Quick Summary
This study reviewed research on cognitive behavioural therapy (CBT) for ME/CFS and found that it helps only a small number of patients with mild symptoms experience temporary subjective fatigue improvement. The improvement didn't translate into better physical fitness, job status, or disability benefits. Safety concerns were largely unreported in the original studies, but patient reports suggest about 1 in 5 people experienced negative outcomes.
Why It Matters
This critique challenges the widespread clinical recommendation of CBT as a primary treatment for ME/CFS and raises important questions about therapeutic efficacy standards and patient safety monitoring. For patients, it validates concerns about CBT's limited effectiveness and calls attention to potentially underreported harms. This work supports the need for better safety surveillance and more rigorous efficacy standards in ME/CFS treatment research.
Observed Findings
Seven patients with mild CFS must be treated with CBT for one to report a small, short-lived subjective improvement in fatigue.
Objective measures of physical fitness showed no improvement despite subjective fatigue reports.
Employment and illness benefit status did not change with CBT treatment.
Most trials in the Cochrane review failed to systematically report safety data or adverse reactions.
Patient evidence suggests adverse outcomes occurred in approximately 20% of CBT cases.
Inferred Conclusions
CBT should be downgraded from a primary treatment to an adjunctive support-level therapy for ME/CFS.
The safety profile of CBT in ME/CFS is inadequately monitored and potentially concerning by pharmaceutical/surgical standards.
Subjective symptom improvement without objective functional improvement raises questions about the clinical meaningfulness of reported CBT benefits.
Current trial design and reporting standards for CBT in ME/CFS are insufficient for establishing treatment safety and efficacy.
Remaining Questions
Why do adverse outcomes occur in approximately 20% of patients, and what patient characteristics predict negative responses to CBT?
What This Study Does Not Prove
This re-analysis does not prove CBT causes harm in all patients, nor does it establish that CBT is never helpful for any CFS-related symptoms. It does not directly measure biological mechanisms or establish definitive causation of reported adverse outcomes. The study is limited to re-analyzing existing Cochrane review data rather than conducting new primary research.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedWeak Case DefinitionMixed Cohort